

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: : Docket No: 2003.793 US
Jeroen A. D. M. TONNAER :

Serial No: Even Date Herewith :
International Application No.: PCT/EP2004/051069 :
International Filing Date: June 9, 2004 :

Title: ASENAPINE FOR THE TREATMENT OF :
SCHIZOPHRENIA IN A PATIENT WITH :
OVERWEIGHT OR PREDISPOSITION FOR :
OVERWEIGHT :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with the requirements of 37 CFR §1.56, applicants submit the documents attached hereto. Pursuant to the United States Patent and Trademark Office, OG Notice 05 August 2003, applicants have excluded the two (2) U.S. patent documents from the attachment. A listing of said documents on form PTO-1449 is also attached. All documents listed on the PTO-1449 are to be made of record in the above-identified case.

The present Information Disclosure Statement is being filed within three months of the date of entry into the U.S. National Stage; therefore, no filing fee is believed to be required. If a filing fee is required, the Commissioner is hereby authorized to charge applicants' deposit account 01-1350 for the full amount of said fee.

A copy of the International Search Report dated November 29, 2004 is enclosed herewith.

This Statement is not intended to represent that no better art exists. Applicants reserve the right to contest the applicability of the documents attached hereto as prior art in the event that any information is discovered which demonstrates that said documents do not qualify as prior art.

Consideration of the present Information Disclosure Statement is respectfully requested. The claimed invention is, however, deemed to represent a patentable departure from the teachings of the prior art.

Respectfully submitted,



Lainie E. Parker
Attorney for Applicant(s)
Registration No.: 36,123

Akzo Nobel Inc.
Intellectual Property Dept.
7 Livingstone Avenue
Dobbs Ferry, NY 10522-3408
(914) 674-5466

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO-1449 (modified)			Atty. Docket # 2003.793 US		Serial No. Unassigned		
			Applicant Jeroen A. D. M. TONNAER				
			Filing Date Even Date Herewith		Group Art Unit Unassigned		
U.S. PATENT DOCUMENTS							
Init	Document Number	Date	Name	Class	Subclass	Filing Date	
	5,763,476	06-1998	Delbressine et al.	514	410		
	2002/0156067 A1	10-2002	Wong et al.	514	220		
FOREIGN PATENT DOCUMENTS							
Document Number	Publ. Date	Country	Class	Subclass	Translation		
					Yes	No	
	WO 95/23600 A1	09-1995	PCT International	A61K	31/40		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) continued on page 2							
	International Search Report No. PCT/EP2004/051069 dated November 29, 2004.						
	Miguel-Hidalgo, J.J., "Org-5222 NV Organon," Current Opinion in CPNS Investigational Drugs, Pharma Press, London, GB, Vol. 2, No. 1, 2000, pp. 85-92.						
	"Org-5222; Antipsychotic, Dopamine D ₂ Receptor Antagonist, 5-HT ₂ Receptor Antagonist," Drugs of the Future, Barcelona, ES, Vol. 18, No. 12, 1993, pp. 1117-1123.						
	Sartorius, N. et al., "The Usefulness and Use of Second-Generation Antipsychotic Medications: Preface," Current Opinion in Psychiatry, United Kingdom, Vol. 15, Suppl. 1, 2002, pp. S1-S51.						
	McIntyre, R. S. et al., "Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities," Canadian Journal of Psychiatry, Vol. 46, No. 3, 2001, pp. 273-281.						
	Sussman, N., "Review of Atypical Antipsychotics and Weight Gain," The Journal of Clinical Psychiatry, U.S., Vol. 62, Suppl. 23, 2001, pp. 5-12.						
	Russell, J. M. et al., "Bodyweight Gain Associated with Atypical Antipsychotics: Epidemiology and Therapeutic Implications," CNS Drugs, New Zealand, Vol. 15, No. 7, 2001, pp. 537-551.						
	Blin, O. et al., "Antipsychotic-Associated Weight Gain and Clinical Outcome Parameters," The Journal of Clinical Psychiatry, U.S., Vol. 62, Suppl. 7, 2001, pp. 11-21.						
	Malhotra, S. et al., "Medical Management of Obesity Associated with Mental Disorders," The Journal of Clinical Psychiatry, U.S., Vol. 63, Suppl. 4, 2002, pp. 24-32.						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

